Eli Lillyvs.Insulet
LLY vs PODD · both in Diabetes & metabolic disease, part of the Medicine, pharma & life science value chain: Treatment and monitoring of diabetes and metabolic disease — from insulin to glucose monitoring.
Eli Lilly is about 100× larger than Insulet by market cap; Insulet trades at the lower P/E (36.9 vs 44.3); year to date, Eli Lilly leads (+10.6% vs −43.3%).
Side by side
| LLY | PODD | |
|---|---|---|
| Market cap | $1.1T | $11.2B |
| Price | $1,188.58 | $161.28 |
| Today | −2.3% | +1.9% |
| Return YTD | +10.6% | −43.3% |
| Return 1Y | +50.3% | −45.8% |
| P/E | 44.3 | 36.9 |
| P/S | 15.5 | 3.9 |
| P/B | 35.9 | 7.4 |
Data as of 2026-07-11 · updates daily after U.S. close
The two companies
Eli LillyLLY
American pharmaceutical group with one of the industry's strongest pipelines — GLP-1 products Mounjaro and Zepbound, alongside treatments in diabetes, oncology and neurology.
Full LLY profile →InsuletPODD
American medtech company known for Omnipod — a tubeless insulin pump for diabetes management.
Full PODD profile →More comparisons in Diabetes & metabolic disease
See where LLY and PODD sit in the full Medicine, pharma & life science map — every segment from suppliers to end markets.Open the Life science value chain →